The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.

Malam, Yogeshkumar; Rabie, Mohamed; Geropantas, Konstantinos; Alexander, Susanna; Pain, Simon; Youssef, Mina

Malam, Yogeshkumar; Rabie, Mohamed; Geropantas, Konstantinos; Alexander, Susanna; Pain, Simon; Youssef, Mina.

Afiliação

Malam Y; Department of Breast Surgery, Norfolk and Norwich University Hospital Trust, Norwich, UK.
Rabie M; Department of Breast Surgery, Norfolk and Norwich University Hospital Trust, Norwich, UK.
Geropantas K; Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Alexander S; Department of Oncology, Norfolk and Norwich University Hospital Trust, Norwich, UK.
Pain S; Department of Oncology, Norfolk and Norwich University Hospital Trust, Norwich, UK.
Youssef M; Department of Breast Surgery, Norfolk and Norwich University Hospital Trust, Norwich, UK.

Cancer Rep (Hoboken) ; 5(8): e1546, 2022 08.

Article em En | MEDLINE | ID: mdl-34664429

Assuntos

Neoplasias da Mama; Neoplasias da Mama/diagnóstico; Neoplasias da Mama/tratamento farmacológico; Neoplasias da Mama/genética; Quimioterapia Adjuvante; Tomada de Decisões; Feminino; Humanos; Receptores de Estrogênio/metabolismo; Receptores de Estrogênio/uso terapêutico; Estudos Retrospectivos

Palavras-chave

Oncotype DX; adjuvant chemotherapy; breast cancer; gene based assay; node positive

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Cancer Rep (Hoboken) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google